Literature DB >> 36114434

Acetate restores hypothalamic-adipose kisspeptin status in a rat model of PCOS by suppression of NLRP3 immunoreactivity.

Kehinde S Olaniyi1, Stephanie E Areloegbe2, Mosunmola B Oyeleke2.   

Abstract

PURPOSE: Polycystic ovary syndrome (PCOS) is a complex reproductive event that is delineated by endocrine/metabolic disorders. Alteration of kisspeptin status in the hypothalamus and adipose tissue is critical to increased endocrine/metabolic derangements in PCOS individuals, aggravating the clinical manifestation of PCOS and its complications. Short chain fatty acids (SCFAs) are crucial modulators of metabolic homeostasis. However, the role of SCFAs, particularly acetate on hypothalamic-adipose kisspeptin status (HAKS) in PCOS model is unknown. The present study hypothesized acetate as a key player in restoration of deranged HAKS, associated with experimental PCOS model.
METHODS: Three groups (n = 6/group) of female Wistar rats (120-150 g) were used. The groups were treated (po) for 21 days with vehicle, letrozole (1 mg/kg) with/without acetate (200 mg/kg) respectively.
RESULTS: Letrozole-treated animals had impaired glucose homeostasis, elevated testosterone, leptin and LH/FSH ratio and decreased GnRH and adiponectin with ovarian tissues revealing degenerated follicles and disrupted morphology. These animals also showed increased concentration of hypothalamic triglyceride (TG)/total cholesterol (TC), free fatty acid (FFA), and decreased concentration of TG/TC/FFA in visceral adipose tissue (VAT) with an increase in hypothalamic and VAT malondialdehyde, NF-κB/TNF-α and decreased glutathione/G6PD and hypothalamic but not VAT kisspeptin. Immunohistochemical analysis revealed the expression of NLRP3 inflammasome in the hypothalamus and VAT and all these changes were attenuated by acetate.
CONCLUSIONS: Altogether, the present results demonstrate that PCOS is characterized with hypothalamic-adipose inflammation, associated with immunohistochemical expression of NLRP3 with significant alteration of hypothalamic but not adipose kisspeptin. The results suggest that acetate restores kisspeptin status in PCOS animals. This beneficial effect is accompanied by repressed NLRP3 immunoreactivity.
© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Acetate; Adipose; Hypothalamus; Kisspeptin; Letrozole; PCOS

Year:  2022        PMID: 36114434     DOI: 10.1007/s12020-022-03191-9

Source DB:  PubMed          Journal:  Endocrine        ISSN: 1355-008X            Impact factor:   3.925


  35 in total

1.  Perspectives on Polycystic Ovary Syndrome: Is Polycystic Ovary Syndrome Research Underfunded?

Authors:  Soumia Brakta; Daria Lizneva; Kateryna Mykhalchenko; Adonis Imam; Walidah Walker; Michael P Diamond; Ricardo Azziz
Journal:  J Clin Endocrinol Metab       Date:  2017-12-01       Impact factor: 5.958

Review 2.  Polycystic ovary syndrome and environmental toxins.

Authors:  Aleksandra Zofia Rutkowska; Evanthia Diamanti-Kandarakis
Journal:  Fertil Steril       Date:  2016-08-22       Impact factor: 7.329

Review 3.  Health care-related economic burden of the polycystic ovary syndrome during the reproductive life span.

Authors:  Ricardo Azziz; Catherine Marin; Lalima Hoq; Enkhe Badamgarav; Paul Song
Journal:  J Clin Endocrinol Metab       Date:  2005-06-08       Impact factor: 5.958

Review 4.  Genetic investigation into ethnic disparity in polycystic ovarian syndrome.

Authors:  Shuxia Li; Dongyi Zhu; Hongmei Duan; Qihua Tan
Journal:  Gynecol Endocrinol       Date:  2013-07-29       Impact factor: 2.260

5.  Reduced ovarian glyoxalase-I activity by dietary glycotoxins and androgen excess: a causative link to polycystic ovarian syndrome.

Authors:  Eleni Kandaraki; Antonis Chatzigeorgiou; Christina Piperi; Eleni Palioura; Sotiria Palimeri; Penelope Korkolopoulou; Michael Koutsilieris; Athanasios G Papavassiliou
Journal:  Mol Med       Date:  2012-10-24       Impact factor: 6.354

Review 6.  Insulin Resistance and Polycystic Ovary Syndrome.

Authors:  Paolo Moghetti
Journal:  Curr Pharm Des       Date:  2016       Impact factor: 3.116

Review 7.  The management of anovulatory infertility in women with polycystic ovary syndrome: an analysis of the evidence to support the development of global WHO guidance.

Authors:  Adam H Balen; Lara C Morley; Marie Misso; Stephen Franks; Richard S Legro; Chandrika N Wijeyaratne; Elisabet Stener-Victorin; Bart C J M Fauser; Robert J Norman; Helena Teede
Journal:  Hum Reprod Update       Date:  2016-08-10       Impact factor: 15.610

8.  Nitric oxide (NO) levels in patients with polycystic ovary syndrome (PCOS): a meta-analysis.

Authors:  Chan Meng
Journal:  J Int Med Res       Date:  2019-08-21       Impact factor: 1.671

9.  Measuring the global disease burden of polycystic ovary syndrome in 194 countries: Global Burden of Disease Study 2017.

Authors:  Jingjing Liu; Qunhong Wu; Yanhua Hao; Mingli Jiao; Xing Wang; Shengchao Jiang; Liyuan Han
Journal:  Hum Reprod       Date:  2021-03-18       Impact factor: 6.918

10.  Treatment of infertility in women with polycystic ovary syndrome: approach to clinical practice.

Authors:  Anderson Sanches Melo; Rui Alberto Ferriani; Paula Andrea Navarro
Journal:  Clinics (Sao Paulo)       Date:  2015-11       Impact factor: 2.365

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.